30 October 2019
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding pharmaceutical HTA and reimbursement decisions.......
Evalumade provides a unique and visual update of Health Technology Assessment decisions made by major institutions worldwide.
Precision, real-time tracking, easy-to-use formats make Evalumade the most innovative global HTA database, voted in by major pharmaceuticals companies and market access actors.
Dedicated to market access leaders, Evalumade offers clear top-level visual information about HTA decisions:
Prioritis is a global provider in market access solutions for pharmaceutical, biotechnology and medical devices. Prioritis undertakes support for pricing and reimbursement processes for new innovative drugs, extension of indications and reassessment of therapeutic areas.
Prismaccess platform contains a comprehensive, detailed record of HTA authorities’ decisions extracted into easy to navigate summaries.
It provides an integrated service to support decision making at all stage of the product’s life with detailed information on recommendations, clinical and economic limitations.